Suppr
超能文献

Biomarkers: exceptional responders-discovering predictive biomarkers.

作者信息

Takebe Naoko, McShane Lisa, Conley Barbara

机构信息

Division of Cancer Treatment and Diagnosis, National Cancer Institute, National Institute of Health, 9609 Medical Center Drive MSC9739, Bethesda, MD 20852, USA.

出版信息

Nat Rev Clin Oncol. 2015 Mar;12(3):132-4. doi: 10.1038/nrclinonc.2015.19. Epub 2015 Feb 17.

DOI:10.1038/nrclinonc.2015.19

PMID:25687910

Abstract

摘要

相似文献

Biomarkers: exceptional responders-discovering predictive biomarkers.

Nat Rev Clin Oncol. 2015 Mar;12(3):132-4. doi: 10.1038/nrclinonc.2015.19. Epub 2015 Feb 17.

microRNAs and Personalized Medicine: Evaluating Their Potential as Cancer Biomarkers.

Adv Exp Med Biol. 2015;888:5-15. doi: 10.1007/978-3-319-22671-2_2.

Exceptional Responders Inspire Change: Lessons for Drug Development From the Bedside to the Bench and Back.

Oncologist. 2015 Jul;20(7):699-701. doi: 10.1634/theoncologist.2014-0476. Epub 2015 Jun 3.

Brave-ish New World--What's Needed to Make Precision Oncology a Practical Reality.

JAMA Oncol. 2015 Oct;1(7):879-80. doi: 10.1001/jamaoncol.2015.1540.

[Great potential of miRNAs as predictive and prognostic markers for cancer].

Zhongguo Fei Ai Za Zhi. 2013 Jan;16(1):C1-4. doi: 10.3779/j.issn.1009-3419.2013.01.12.

Cancer Diagnostic and Predictive Biomarkers 2015.

Biomed Res Int. 2015;2015:235985. doi: 10.1155/2015/235985. Epub 2015 Oct 12.

Bioanalysis for precision medicine.

Bioanalysis. 2019 Jun;11(11):1039-1043. doi: 10.4155/bio-2019-0106.

Shifting to a Biomarker Paradigm Across Cancer Care.

Clin J Oncol Nurs. 2020 Dec 1;24(6):633-634. doi: 10.1188/20.CJON.633-634.

Predictive pathology in routine diagnostics of solid tumors.

Histol Histopathol. 2012 Mar;27(3):289-96. doi: 10.14670/HH-27.289.

The patent eligibility of personalized medicine technologies.

J Leg Med. 2014;35(3):423-31. doi: 10.1080/01947648.2014.936264.

引用本文的文献

Evaluating the potential of GSPT2 and CIRBP as biomarkers in endometrial cancer: Multicenter RT-PCR and IHC study.

Medicine (Baltimore). 2025 Aug 29;104(35):e43627. doi: 10.1097/MD.0000000000043627.

Oncogenic Activity and Sorafenib Sensitivity of p.S214C Mutation in Lung Cancer.

Cancers (Basel). 2025 Jul 4;17(13):2246. doi: 10.3390/cancers17132246.

EPHX2 overexpression deters the advancement of clear cell renal cell carcinoma via lipid metabolism reprogramming.

Front Oncol. 2025 Jun 5;15:1541429. doi: 10.3389/fonc.2025.1541429. eCollection 2025.

Inflammatory Microenvironment in Early Non-Small Cell Lung Cancer: Exploring the Predictive Value of Radiomics.

Cancers (Basel). 2022 Jul 8;14(14):3335. doi: 10.3390/cancers14143335.

Advances in Pharmacotherapy of Hepatocellular Carcinoma: A State-of-the-Art Review.

Dig Dis. 2022;40(5):565-580. doi: 10.1159/000520095. Epub 2021 Oct 13.

The Exceptional Responders Initiative: Feasibility of a National Cancer Institute Pilot Study.

J Natl Cancer Inst. 2021 Jan 4;113(1):27-37. doi: 10.1093/jnci/djaa061.

Precision medicine and actionable alterations in lung cancer: A single institution experience.

PLoS One. 2020 Feb 11;15(2):e0228188. doi: 10.1371/journal.pone.0228188. eCollection 2020.

Going to extremes: determinants of extraordinary response and survival in patients with cancer.

Nat Rev Cancer. 2019 Jun;19(6):339-348. doi: 10.1038/s41568-019-0145-5.

Master protocol trials in oncology: Review and new trial designs.

Contemp Clin Trials Commun. 2018 Aug 24;12:1-8. doi: 10.1016/j.conctc.2018.08.009. eCollection 2018 Dec.

Exploiting vulnerabilities in cancer signalling networks to combat targeted therapy resistance.

Essays Biochem. 2018 Oct 26;62(4):583-593. doi: 10.1042/EBC20180016.

本文引用的文献

Rationale for co-targeting IGF-1R and ALK in ALK fusion-positive lung cancer.

Nat Med. 2014 Sep;20(9):1027-34. doi: 10.1038/nm.3667. Epub 2014 Aug 31.

Molecular analysis for therapy choice: NCI MATCH.

Semin Oncol. 2014 Jun;41(3):297-9. doi: 10.1053/j.seminoncol.2014.05.002. Epub 2014 May 22.

Synthetic lethality in ATM-deficient RAD50-mutant tumors underlies outlier response to cancer therapy.

Cancer Discov. 2014 Sep;4(9):1014-21. doi: 10.1158/2159-8290.CD-14-0380. Epub 2014 Jun 16.

Learning from exceptional drug responders.

Nat Rev Drug Discov. 2014 Jun;13(6):401-2. doi: 10.1038/nrd4338.

National Cancer Institute's Precision Medicine Initiatives for the new National Clinical Trials Network.

Am Soc Clin Oncol Educ Book. 2014:71-6. doi: 10.14694/EdBook_AM.2014.34.71.

Activating mTOR mutations in a patient with an extraordinary response on a phase I trial of everolimus and pazopanib.

Cancer Discov. 2014 May;4(5):546-53. doi: 10.1158/2159-8290.CD-13-0353. Epub 2014 Mar 13.

Genome sequencing identifies a basis for everolimus sensitivity.

Science. 2012 Oct 12;338(6104):221. doi: 10.1126/science.1226344. Epub 2012 Aug 23.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

相似文献

Biomarkers: exceptional responders-discovering predictive biomarkers.

Nat Rev Clin Oncol. 2015 Mar;12(3):132-4. doi: 10.1038/nrclinonc.2015.19. Epub 2015 Feb 17.

microRNAs and Personalized Medicine: Evaluating Their Potential as Cancer Biomarkers.

Adv Exp Med Biol. 2015;888:5-15. doi: 10.1007/978-3-319-22671-2_2.

Exceptional Responders Inspire Change: Lessons for Drug Development From the Bedside to the Bench and Back.

Oncologist. 2015 Jul;20(7):699-701. doi: 10.1634/theoncologist.2014-0476. Epub 2015 Jun 3.

Brave-ish New World--What's Needed to Make Precision Oncology a Practical Reality.

JAMA Oncol. 2015 Oct;1(7):879-80. doi: 10.1001/jamaoncol.2015.1540.

[Great potential of miRNAs as predictive and prognostic markers for cancer].

Zhongguo Fei Ai Za Zhi. 2013 Jan;16(1):C1-4. doi: 10.3779/j.issn.1009-3419.2013.01.12.

Cancer Diagnostic and Predictive Biomarkers 2015.

Biomed Res Int. 2015;2015:235985. doi: 10.1155/2015/235985. Epub 2015 Oct 12.

Bioanalysis for precision medicine.

Bioanalysis. 2019 Jun;11(11):1039-1043. doi: 10.4155/bio-2019-0106.

Shifting to a Biomarker Paradigm Across Cancer Care.

Clin J Oncol Nurs. 2020 Dec 1;24(6):633-634. doi: 10.1188/20.CJON.633-634.

Predictive pathology in routine diagnostics of solid tumors.

Histol Histopathol. 2012 Mar;27(3):289-96. doi: 10.14670/HH-27.289.

The patent eligibility of personalized medicine technologies.

J Leg Med. 2014;35(3):423-31. doi: 10.1080/01947648.2014.936264.

引用本文的文献

Evaluating the potential of GSPT2 and CIRBP as biomarkers in endometrial cancer: Multicenter RT-PCR and IHC study.

Medicine (Baltimore). 2025 Aug 29;104(35):e43627. doi: 10.1097/MD.0000000000043627.

Oncogenic Activity and Sorafenib Sensitivity of p.S214C Mutation in Lung Cancer.

Cancers (Basel). 2025 Jul 4;17(13):2246. doi: 10.3390/cancers17132246.

EPHX2 overexpression deters the advancement of clear cell renal cell carcinoma via lipid metabolism reprogramming.

Front Oncol. 2025 Jun 5;15:1541429. doi: 10.3389/fonc.2025.1541429. eCollection 2025.

Inflammatory Microenvironment in Early Non-Small Cell Lung Cancer: Exploring the Predictive Value of Radiomics.

Cancers (Basel). 2022 Jul 8;14(14):3335. doi: 10.3390/cancers14143335.

Advances in Pharmacotherapy of Hepatocellular Carcinoma: A State-of-the-Art Review.

Dig Dis. 2022;40(5):565-580. doi: 10.1159/000520095. Epub 2021 Oct 13.

The Exceptional Responders Initiative: Feasibility of a National Cancer Institute Pilot Study.

J Natl Cancer Inst. 2021 Jan 4;113(1):27-37. doi: 10.1093/jnci/djaa061.

Precision medicine and actionable alterations in lung cancer: A single institution experience.

PLoS One. 2020 Feb 11;15(2):e0228188. doi: 10.1371/journal.pone.0228188. eCollection 2020.

Going to extremes: determinants of extraordinary response and survival in patients with cancer.

Nat Rev Cancer. 2019 Jun;19(6):339-348. doi: 10.1038/s41568-019-0145-5.

Master protocol trials in oncology: Review and new trial designs.

Contemp Clin Trials Commun. 2018 Aug 24;12:1-8. doi: 10.1016/j.conctc.2018.08.009. eCollection 2018 Dec.

Exploiting vulnerabilities in cancer signalling networks to combat targeted therapy resistance.

Essays Biochem. 2018 Oct 26;62(4):583-593. doi: 10.1042/EBC20180016.

本文引用的文献

Rationale for co-targeting IGF-1R and ALK in ALK fusion-positive lung cancer.

Nat Med. 2014 Sep;20(9):1027-34. doi: 10.1038/nm.3667. Epub 2014 Aug 31.

Molecular analysis for therapy choice: NCI MATCH.

Semin Oncol. 2014 Jun;41(3):297-9. doi: 10.1053/j.seminoncol.2014.05.002. Epub 2014 May 22.

Synthetic lethality in ATM-deficient RAD50-mutant tumors underlies outlier response to cancer therapy.

Cancer Discov. 2014 Sep;4(9):1014-21. doi: 10.1158/2159-8290.CD-14-0380. Epub 2014 Jun 16.

Learning from exceptional drug responders.

Nat Rev Drug Discov. 2014 Jun;13(6):401-2. doi: 10.1038/nrd4338.

National Cancer Institute's Precision Medicine Initiatives for the new National Clinical Trials Network.

Am Soc Clin Oncol Educ Book. 2014:71-6. doi: 10.14694/EdBook_AM.2014.34.71.

Activating mTOR mutations in a patient with an extraordinary response on a phase I trial of everolimus and pazopanib.

Cancer Discov. 2014 May;4(5):546-53. doi: 10.1158/2159-8290.CD-13-0353. Epub 2014 Mar 13.

Genome sequencing identifies a basis for everolimus sensitivity.

Science. 2012 Oct 12;338(6104):221. doi: 10.1126/science.1226344. Epub 2012 Aug 23.

Suppr超能文献

Biomarkers: exceptional responders-discovering predictive biomarkers.

作者信息

机构信息

出版信息

相似文献

引用本文的文献

本文引用的文献

文献AI研究员

用中文搜PubMed

文档翻译